Rate My Professor David Mushatt

David Mushatt, MD, MPH&TM, FIDSA, FACP, is a Professor of Medicine and Section Chief of the Infectious Diseases Section at Tulane University School of Medicine. He received his MD from Harvard Medical School in 1986, followed by internal medicine residency training at the Harvard-affiliated Brigham and Women’s Hospital in Boston from 1986 to 1989. He then completed an Infectious Diseases fellowship at Tulane University School of Medicine from 1989 to 1991, during which he earned an MPH in Tropical Medicine from the Tulane School of Public Health and Tropical Medicine. Dr. Mushatt joined the Tulane Infectious Diseases Section immediately after his fellowship as an Assistant Professor in 1991. He became Director of the Infectious Diseases Fellowship Program in 2002 and was promoted to Section Chief in 2006. In addition to his leadership roles, he has served as Vice-Chairman of the Tulane Institutional Review Board, contributing to human research subjects protections.

Dr. Mushatt's primary research interest is HIV clinical trials, for which he serves as Principal Investigator of the Louisiana Community AIDS Research Program, Tulane’s clinical trials site formerly part of the CPCRA and now integrated into the NIH-funded INSIGHT international HIV research network focusing on community-level treatment strategies. His clinical interests encompass HIV medicine, fungal and mycobacterial infections, orthopedic infections, and zoonoses. He is actively involved in teaching medical students, residents, and fellows. Dr. Mushatt holds fellowships from the Infectious Diseases Society of America (FIDSA) and the American College of Physicians (FACP), and received the Best Subspecialty Attending Award from the Tulane Medicine Residency Program in 2008. His key publications include "Neurologic aspects of North American zoonoses" in Infectious Disease Clinics of North America (1991), "Successful treatment of Mycobacterium abscessus infections with multidrug regimens containing clarithromycin" in Clinical Infectious Diseases (1995), "Clinical manifestations and implications of coinfection with Mycobacterium kansasii and human immunodeficiency virus type 1" in Clinical Infectious Diseases (1995), "MSG-01: A randomized, double-blind, placebo controlled trial of caspofungin prophylaxis followed by pre-emptive therapy for invasive candidiasis" in Clinical Infectious Diseases (2014), and "Serum and BAL beta-D-glucan for the diagnosis of Pneumocystis pneumonia in HIV positive patients" in Respiratory Medicine (2014).